Answers are grounded in this paper and cite their sources.
Aim of the study This study investigated the antitumor activity of isoginkgetin (IGK), a biflavonoid derived from Ginkgo biloba L., in esophageal squamous cell carcinoma (ESCC). Methods CCK-8, colony formation, EdU incorporation, wound-healing, Transwell, and flow-cytometric assays were used to characterize IGK-induced phenotypes. Integrated transcriptomic and data-independent acquisition proteomic analyses were used for abundance-based molecular profiling, while targeted antibody-based phosphorylation-array profiling was analyzed as a separate signaling-activity layer. Molecular docking and 100-ns molecular dynamics simulations assessed binding plausibility. SPR quantified direct IGK-PLEKHA5 binding, CETSA assessed IGK-dependent PLEKHA5 thermal stabilization, PLEKHA5 -overexpression experiments tested functional relevance, and a nude-mouse subcutaneous xenograft model assessed in vivo antitumor activity and tolerability within the measured endpoints. Results IGK inhibited ESCC cell proliferation, colony formation, migration, and invasion and induced G2/M arrest and apoptosis. Transcriptomic and proteomic profiles primarily reflected broad changes in cell-cycle, DNA-repair, p53-associated, and stress-response programs. Targeted phosphorylation-array analysis and immunoblotting showed reduced AKT and mTOR phosphorylation, together with changes in MAPK/ERK, GSK3α, and CREB-related signals. Cross-platform analysis showed significantly reduced PLEKHA5 protein abundance, accompanied by a downward trend in PLEKHA5 transcript expression. SPR showed concentration-dependent IGK-PLEKHA5 binding with an apparent equilibrium dissociation constant (K D ) of 9.266 μM, and CETSA showed IGK-dependent thermal stabilization of PLEKHA5. PLEKHA5 overexpression partially restored malignant phenotypes and AKT/mTOR phosphorylation. In vivo , IGK reduced xenograft growth and intratumoral PLEKHA5, p-AKT, p-mTOR, and Ki-67 signals without overt renal injury or increases in the measured inflammatory markers under the tested schedule. Conclusion These findings support PLEKHA5 as a direct binding target of IGK and indicate that PLEKHA5 contributes to the attenuation of AKT/mTOR signaling and the antitumor response in ESCC. The partial rescue following PLEKHA5 overexpression further suggests that additional IGK-responsive mechanisms are also involved.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: